Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in adults with moderate to severe systemic lupus erythematosus
ISRCTN15146958Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: SLE SRI-4 composite response at Week 52. Started Mar 2026; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ISRCTN15146958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15146958.